Total Payments
$3,491
2024 Payments
$213.44
Companies
34
Transactions
145
Medicare Patients
6,662
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$3,348 (95.9%)
Travel$117.46 (3.4%)
Education$24.81 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,348 | 143 | 95.9% |
| Travel and Lodging | $117.46 | 1 | 3.4% |
| Education | $24.81 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic USA, Inc. | $686.37 | 25 | $0 (2019) |
| SI-BONE, INC. | $401.21 | 9 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $361.60 | 23 | $0 (2024) |
| Medtronic, Inc. | $333.10 | 10 | $0 (2022) |
| PFIZER INC. | $194.66 | 14 | $0 (2021) |
| GRT US Holding, Inc. | $153.62 | 9 | $0 (2022) |
| Boston Scientific Corporation | $147.78 | 6 | $0 (2024) |
| US WorldMeds, LLC | $133.87 | 2 | $0 (2019) |
| AbbVie Inc. | $125.00 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $121.34 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $213.44 | 8 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($83.12) |
| 2023 | $218.51 | 9 | ACADIA Pharmaceuticals Inc ($85.15) |
| 2022 | $674.65 | 22 | SI-BONE, Inc. ($245.41) |
| 2021 | $645.16 | 29 | Medtronic, Inc. ($146.71) |
| 2020 | $186.82 | 13 | PFIZER INC. ($88.14) |
| 2019 | $711.43 | 31 | Medtronic USA, Inc. ($223.25) |
| 2018 | $668.75 | 25 | Medtronic USA, Inc. ($405.12) |
| 2017 | $171.96 | 8 | Medtronic USA, Inc. ($58.00) |
All Payment Transactions
145 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: Gastroenterology | ||||||
| 10/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Gastroenterology | ||||||
| 08/22/2024 | Stryker Corporation | SPINEJACK (Device) | Food and Beverage | In-kind items and services | $56.92 | General |
| Category: SPINE | ||||||
| 08/01/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $17.58 | General |
| 07/10/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: Gastroenterology | ||||||
| 02/06/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: PAIN MANAGEMENT | ||||||
| 01/10/2024 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $32.79 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 01/10/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: Gastroenterology | ||||||
| 12/28/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/11/2023 | SI-BONE, INC. | — | Food and Beverage | Cash or cash equivalent | $15.11 | General |
| 11/15/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: Gastroenterology | ||||||
| 10/25/2023 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $85.15 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/15/2023 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $17.40 | General |
| Category: Opioid Analgesic | ||||||
| 05/09/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: Gastroenterology | ||||||
| 03/20/2023 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $19.46 | General |
| Category: Opioid Analgesic | ||||||
| 03/03/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: INSOMNIA | ||||||
| 01/25/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Gastroenterology | ||||||
| 11/05/2022 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $53.76 | General |
| Category: Neuropsychiatry | ||||||
| 10/24/2022 | SI-BONE, Inc. | — | Food and Beverage | Cash or cash equivalent | $147.51 | General |
| 09/26/2022 | Merck Sharp & Dohme LLC | BELSOMRA (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: NEUROSCIENCE | ||||||
| 09/16/2022 | SI-BONE, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.92 | General |
| 09/07/2022 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $6.61 | General |
| Category: Pain Management | ||||||
| 08/15/2022 | GRT US Holding, Inc. | Qutenza (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Pain Management | ||||||
| 08/01/2022 | Merck Sharp & Dohme LLC | BELSOMRA (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,379 | 3,490 | $837,698 | $311,981 |
| 2022 | 19 | 1,560 | 4,142 | $1.0M | $377,550 |
| 2021 | 20 | 1,799 | 4,750 | $1.3M | $488,565 |
| 2020 | 21 | 1,924 | 3,538 | $1.0M | $337,617 |
Total Patients
6,662
Total Services
15,920
Medicare Billing
$1.5M
Procedure Codes
79
All Medicare Procedures & Services
79 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 234 | 1,107 | $228,456 | $93,821 | 41.1% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 199 | 483 | $144,600 | $54,164 | 37.5% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 207 | 480 | $143,700 | $29,232 | 20.3% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 54 | 69 | $53,884 | $26,394 | 49.0% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2023 | 82 | 118 | $56,121 | $20,171 | 35.9% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 66 | 66 | $39,300 | $15,971 | 40.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 67 | 232 | $32,929 | $13,880 | 42.2% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 53 | 67 | $21,342 | $13,548 | 63.5% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2023 | 36 | 77 | $25,056 | $10,892 | 43.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 65 | 65 | $20,449 | $7,450 | 36.4% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2023 | 36 | 77 | $13,003 | $6,137 | 47.2% |
| 64633 | Destruction of upper or middle spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 13 | 15 | $11,802 | $5,342 | 45.3% |
| 77002 | Fluoroscopic guidance for needle placement | Office | 2023 | 47 | 65 | $12,817 | $5,163 | 40.3% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 51 | 72 | $8,525 | $3,098 | 36.3% |
| 64634 | Destruction of upper or middle spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 12 | 14 | $4,878 | $3,015 | 61.8% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Office | 2023 | 52 | 78 | $9,270 | $2,628 | 28.4% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 13 | 15 | $1,849 | $596.74 | 32.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 68 | 364 | $9,100 | $286.21 | 3.1% |
| 99153 | Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | Office | 2023 | 24 | 26 | $616.98 | $191.25 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 253 | 1,236 | $255,430 | $107,659 | 42.1% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 224 | 539 | $161,700 | $60,711 | 37.5% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 231 | 551 | $165,300 | $33,711 | 20.4% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2022 | 53 | 92 | $71,587 | $29,087 | 40.6% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2022 | 52 | 128 | $39,987 | $21,920 | 54.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 86 | 319 | $45,320 | $17,973 | 39.7% |
About Dr. Daniel Lynch, MD
Dr. Daniel Lynch, MD is a Interventional Pain Medicine healthcare provider based in Louisville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922027705.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Lynch, MD has received a total of $3,491 in payments from pharmaceutical and medical device companies, with $213.44 received in 2024. These payments were reported across 145 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($3,348).
As a Medicare-enrolled provider, Lynch has provided services to 6,662 Medicare beneficiaries, totaling 15,920 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 79 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Pain Medicine
- Other Specialties Interventional Pain Medicine
- Location Louisville, KY
- Active Since 07/19/2006
- Last Updated 04/27/2020
- Taxonomy Code 208VP0014X
- Entity Type Individual
- NPI Number 1922027705
Products in Payments
- INTELLIS (Device) $401.18
- RELISTOR (Drug) $296.45
- Qutenza (Drug) $153.62
- VECTRIS (Device) $147.98
- Lucemyra/Lofexidine (Drug) $133.87
- VRAYLAR (Drug) $125.00
- SYNCHROMEDII (Device) $120.17
- ASCENDA (Device) $116.26
- SYNCHROMED (Device) $115.89
- LYRICA (Drug) $105.11
- FARXIGA (Drug) $92.49
- iFuse Implant (Device) $89.33
- NUPLAZID (Drug) $85.15
- Zilretta (Drug) $82.03
- Movantik (Drug) $75.66
- Horizant (Drug) $67.43
- INTELLIS ADAPTIVESTIM (Device) $66.22
- LUCEMYRA (Drug) $65.15
- SPINEJACK (Device) $56.92
- INGREZZA (Drug) $53.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Interventional Pain Medicine Doctors in Louisville
Dr. Alexander Sinofsky, M.d, M.D
Interventional Pain Medicine — Payments: $11,809
Interventional Pain Medicine $11,809
Dr. Gary Reasor, M.d, M.D
Interventional Pain Medicine — Payments: $11,801
Interventional Pain Medicine $11,801
Dr. Brandon Sutton, M.d, M.D
Interventional Pain Medicine — Payments: $10,270
Interventional Pain Medicine $10,270
Konrad Kijewski, M.d, M.D
Interventional Pain Medicine — Payments: $9,185
Interventional Pain Medicine $9,185
Mr. Bill Haney, Md, MD
Interventional Pain Medicine — Payments: $9,081
Interventional Pain Medicine $9,081
Larry Zhou, Md, MD
Interventional Pain Medicine — Payments: $6,564
Interventional Pain Medicine $6,564